(η5-C5Me5)RhCO(1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane) | 908356-27-4

• 英文名称: (η5-C5Me5)RhCO(1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane)
• 英文别名: RhCO(η5-C5Me5)(pta)
• CAS: 908356-27-4
• 化学式: C₁₇H₂₇N₃OPRh
• 分子量: 423.3
• InChiKey: MMYMQNZPDKRKNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为产物：
  描述：

  η5-pentamethylcyclopentadienyl rhodium dicarbonyl 、 1,3,5-三氮杂-7-磷杂金刚烷 以 乙醇 为溶剂， 以60%的产率得到(η5-C5Me5)RhCO(1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane)
  参考文献：
  名称：

  In Vitro Evaluation of Rhodium and Osmium RAPTA Analogues:  The Case for Organometallic Anticancer Drugs Not Based on Ruthenium

  摘要：

  Reaction of the dimer [(eta(5)-C5Me5)RhCl(mu(2)-Cl)](2) with 2 or 4 equiv of the water-soluble phosphine 1,3,5-triaza-7-phosphatricyclo[3.3.1.1] decane (pta) affords [Rh(eta(5)-C5Me5)(pta)Cl-2] and [Rh(eta(5)-C5Me5)(pta)(2)Cl] Cl, respectively. Both complexes have been characterized in solution by NMR spectroscopy and in the solid state by single-crystal X-ray diffraction, the latter as the chloride and BPh4- salts. In addition, the rhodium(I) complexes [Rh(eta(5)-C5Me5)(CO)(pta)] and [Rh(eta(5)-C5H5)(pta)(2)] have been prepared lfrom [Rh(eta(5)-C5Me5)(CO)(2)] and [Rh(eta(5)-C5H5)(PPh3)(2)], respectively, by reaction with pta. An in vitro evaluation of these compounds, together with [Os(eta(6)-C10H14)(pta)Cl-2] and the well-characterized antimetastasis drug [Ru(eta(6)-C10H14)(pta)Cl-2], RAPTA-C, was undertaken using HT29 colon carcinoma, A549 lung carcinoma, and T47D breast carcinoma cells. In the HT29 cell line, the two nearest congeners to [Ru(eta(6)-C10H14)(pta)Cl-2], viz., [Rh(eta(5)-C5Me5)(pta)Cl-2] and [Os(eta(6)-C10H14)(pta)Cl-2], demonstrated very similar cytotoxicity profiles. [Rh(eta(5)-C5Me5)(pta)Cl-2] proved significantly more cytotoxic in A549 cells and [Rh(eta(5)-C5Me5)(pta)(2)Cl] Cl 3-fold more cytotoxic in T47D cells, both relative to RAPTA-C. These data suggest that the development of organometallic anticancer drugs based on the neighboring elements to ruthenium should not be overlooked.

  DOI：

  10.1021/om060394o